Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Werewolf Therapeutics, Inc.

$0.36 -2.54% NASDAQ: HOWL · 15-min delayed
  • WATERTOWN, Massachusetts
  • Public · NASDAQ: HOWL
  • 14 employees
$19.1MMarket cap
-$60.8MNet income
14Employees
HOWLNASDAQ
2021IPO

About Werewolf Therapeutics, Inc.

Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Net income
-$60.8M
Total assets
$69.4M
Market cap
$19.1M

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$0
Operating expenses
$60.7M
Operating income
-$60.7M
Income tax
$0
Net income
-$60.8M
EPS (basic)
$-1.32
EPS (diluted)
$-1.33

Balance sheet

Total assets
$69.4M
Current assets
$58.6M
Total liabilities
$44.6M
Current liabilities
$36.1M
Shareholders’ equity
$24.8M

Cash flow

Operating cash flow
-$60.3M
Investing cash flow
$54.3M
Financing cash flow
$6.0M
Net cash flow
$0

Statements via Polygon.io (SEC filings)

NASDAQ: HOWL
$0.36 -2.54%

15-minute delayed · data by Polygon.io

Past year

$0.36 $2.19

52-week range

Market cap
$19.1M
EPS (diluted)
$-1.33
Shares outstanding
53.0M
Open
Day range
Prev close
Volume
IPO date
Apr 30, 2021

Market data by Polygon.io · prices are 15-minute delayed

Auto-generated

At a glance

  • Reported a net loss of $60.8M.
  • Trading 84% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Werewolf Therapeutics, Inc..

Write a review
Newsroom

News about Werewolf Therapeutics, Inc.

News & sentiment via Polygon.io

Explore

Similar companies

Browse all →